GSK/Teva Lamictal settlement
Executive Summary
GlaxoSmithKline and Teva reach agreement in principle to settle patent litigation over anti-epileptic Lamictal. Teva filed lamotrigine ANDA in 2002; pediatric exclusivity expires January 2009 (1"The Pink Sheet" Oct. 28, 2002, p. 11)...
You may also be interested in...
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.